Antibody-Drug Conjugates in Advanced/Metastatic Non–Small Cell Lung Cancer
UBM Medica,
This supplement was supported by AstraZeneca. The contents of this supplement may include information regarding the use of…
2025 ASCO Oral Presentation: Innovent Biologics Announces Updated Data of IBI363 (First-in-class PD-1/IL-2α-bias Bispecific Antibody Fusion Protein) from the Phase 1 PoC Clinical Study in Advanced Non-small Cell Lung Cancer
BioSpace,
SAN FRANCISCO and SUZHOU, China, June 3, 2025 /PRNewswire/ -- Innovent Biologics, Inc.
2025 ASCO Oral Presentation: Innovent Biologics Announces Updated Data of IBI363 (First-in-class PD-1/IL-2α-bias Bispecific Antibody Fusion Protein) from the Phase 1 PoC Clinical Study in Advanced Non-small Cell Lung Cancer
ProfitQuotes.com,
SAN FRANCISCO and SUZHOU, China, June 3, 2025 -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class…
2025 ASCO Oral Presentation: Innovent Biologics Announces Updated Data of IBI363 (First-in-class PD-1/IL-2α-bias Bispecific Antibody Fusion Protein) from the Phase 1 PoC Clinical Study in Advanced Non-small Cell Lung Cancer
Yahoo! Finance USA,
SAN FRANCISCO and SUZHOU, China, June 3, 2025 /PRNewswire/ Innovent Biologics, Inc.